InVivoMAb anti-mouse Delta-like protein 1 (DLL1)

Clone Catalog # Category
HMD1-5 BE0155 InVivoMab Antibodies
$95 - $3250

About InVivoMAb anti-mouse Delta-like protein 1 (DLL1)

The HMD1-5 monoclonal antibody reacts with mouse Delta-like protein 1 (DLL1) one of many Notch ligands. DLL1 is expressed by thymic and splenic stromal cells, macrophages, and dendritic cells. The Notch pathway is an important intercellular signaling pathway that plays a major role in controlling cell fate. The HMD1-5 antibody has been shown to neutralize DLL1 in vivo.

InVivoMAb anti-mouse Delta-like protein 1 (DLL1) Specifications

Isotype

Armenian Hamster IgG, κ

Recommended Isotype Control(s) InVivoMAb polyclonal Armenian hamster IgG(BE0091)
Recommended InVivoPure Dilution Buffer InVivoPure pH 7.0 Dilution Buffer(IP0070)
Immunogen

Mouse DLL1

Reported Applications
  • in vivo DLL1 neutralization
  • Flow cytometry
Endotoxin
  • <2EU/mg (<0.002EU/μg)
  • Determined by LAL gel clotting assay
Purity
  • >95%
  • Determined by SDS-PAGE
Formulation
  • PBS, pH 7.0
  • Contains no stabilizers or preservatives
Sterility

0.2 μM filtered

Production

Purified from tissue culture supernatant in an animal free facility

Purification

Protein G

Storage

The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.

RRID

AB_10950546

Molecular Weight

150 kDa

Application References

InVivoMAb anti-mouse Delta1/ m DLL1 (Clone: HMD1-5)

  Riella, L. V., et al. (2011). "Blockade of Notch ligand delta1 promotes allograft survival by inhibiting alloreactive Th1 cells and cytotoxic T cell generation." J Immunol 187(9): 4629-4638. PubMed

The Notch signaling pathway has been recently shown to contribute to T cell differentiation in vitro. However, the in vivo function of Notch signaling in transplantation remains unknown. In this study, we investigated the importance of Delta1 in regulating the alloimmune response in vivo. Delta1 expression was upregulated on dendritic cells and monocytes/macrophages upon transplantation in a BALB/c into B6 vascularized cardiac transplant model. Whereas administration of anti-Delta1 mAb only slightly delayed survival of cardiac allografts in this fully MHC-mismatched model, it significantly prolonged graft survival in combination with single-dose CTLA4-Ig or in CD28 knockout recipients. The prolongation of allograft survival was associated with Th2 polarization and a decrease in Th1 and granzyme B-producing cytotoxic T cells. The survival benefit of Delta1 blockade was abrogated after IL-4 neutralization and in STAT6KO recipients, but was maintained in STAT4KO recipients, reinforcing the key role of Th2 cell development in its graft-prolonging effects. To our knowledge, these data demonstrate for the first time an important role of Delta1 in alloimmunity, identifying Delta1 ligand as a potential novel target for immunomodulation in transplantation.

We're Heading to AACR

Come visit us at Booth 1842! See you in Atlanta!